These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11449745)

  • 21. Costs and utilization of substance abuse care in a privately insured population under managed care.
    Schoenbaum M; Zhang W; Sturm R
    Psychiatr Serv; 1998 Dec; 49(12):1573-8. PubMed ID: 9856619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating costs of mental health and substance abuse coverage.
    Frank RG; McGuire TG
    Health Aff (Millwood); 1995; 14(3):102-15. PubMed ID: 7498883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mental health and substance abuse coverage under health reform.
    Arons BS; Frank RG; Goldman HH; McGuire TG; Stephens S
    Health Aff (Millwood); 1994; 13(1):192-205. PubMed ID: 8188135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The economic cost of substance abuse treatment in the state of Florida.
    Alexandre PK; Beulaygue IC; French MT; McCollister KE; Popovici I; Sayed BA
    Eval Rev; 2012 Jun; 36(3):167-85. PubMed ID: 22710081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Group psychotherapy of substance abuse in the era of managed mental health care.
    Spitz HI
    Int J Group Psychother; 2001 Jan; 51(1):21-41. PubMed ID: 11191593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using health insurance claims data to analyze substance abuse charges and utilization.
    Garnick DW; Horgan CM; Hendricks AM; Comstock C
    Med Care Res Rev; 1996 Sep; 53(3):350-68. PubMed ID: 10172725
    [No Abstract]   [Full Text] [Related]  

  • 27. Substance abuse day treatment and managed health care.
    Schneider RJ; Herbert M
    J Ment Health Adm; 1992; 19(1):119-24. PubMed ID: 10171034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Financing and payment reform for primary health care and substance abuse treatment.
    Kunnes R; Niven R; Gustafson T; Brooks N; Levin SM; Edmunds M; Trumble JG; Coye MJ
    J Addict Dis; 1993; 12(2):23-42. PubMed ID: 8386551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of health economics in substance abuse research. Recent advances and future opportunities. Overview.
    French MT
    Recent Dev Alcohol; 2001; 15():201-8. PubMed ID: 11449742
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of managed care on access to mental health services among Medicaid enrollees receiving substance treatment.
    Bigelow DA; McFarland BH; McCamant LE; Deck DD; Gabriel RM
    Psychiatr Serv; 2004 Jul; 55(7):775-9. PubMed ID: 15232016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substance abuse and family illness: evidence from health care utilization and cost-offset research.
    Lennox RD; Scott-Lennox JA; Holder HD
    J Ment Health Adm; 1992; 19(1):83-95. PubMed ID: 10171039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of alcohol treatment services.
    French MT
    Recent Dev Alcohol; 2001; 15():209-28. PubMed ID: 11449743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managed care risk contracts and substance abuse treatment.
    Sturm R
    Inquiry; 2000; 37(2):219-25. PubMed ID: 10985114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monetary conversion factors for economic evaluations of substance use disorders.
    McCollister K; Yang X; Sayed B; French MT; Leff JA; Schackman BR
    J Subst Abuse Treat; 2017 Oct; 81():25-34. PubMed ID: 28847452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oregon's transition to a managed care model for Medicaid-funded substance abuse treatment: steamrolling the glass menagerie.
    D'Ambrosio R; Mondeaux F; Gabriel RM; Laws KE
    Health Soc Work; 2003 May; 28(2):126-36. PubMed ID: 12774534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mental health/substance abuse treatment in managed care: the Massachusetts Medicaid experience.
    Callahan JJ; Shepard DS; Beinecke RH; Larson MJ; Cavanaugh D
    Health Aff (Millwood); 1995; 14(3):173-84. PubMed ID: 7498890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A critical review of accounting and economic methods for estimating the costs of addiction treatment.
    Cartwright WS
    J Subst Abuse Treat; 2008 Apr; 34(3):302-10. PubMed ID: 17614244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors.
    Mayer S; Paulus ATG; Łaszewska A; Simon J; Drost RMWA; Ruwaard D; Evers SMAA
    Pharmacoeconomics; 2017 Sep; 35(9):895-908. PubMed ID: 28597368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.